BioLife Solutions (BLFS) CTO share sale for tax withholding

Rhea-AI Filing Summary

BioLife Solutions Inc. reported that Chief Technology Officer Sean Werner executed an open-market sale of 111 shares of common stock on March 3, 2026 at $20.74 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan.

According to the filing, the trading plan, effective February 24, 2022, was established to satisfy tax withholding obligations arising from the vesting of restricted stock. After this sale, Werner directly holds 49,932 shares of BioLife Solutions common stock.

Insider Trade Summary

Net Seller: 111 shares ($2,302)

Net Sell 1 txn

Insider Werner Sean

Role Chief Technology Officer

Sold 111 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	111	$20.74	$2K

Holdings After Transaction: Common Stock — 49,932 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Werner Sean

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S(1)		111	D	$20.74	49,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Sean Werner	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLife Solutions (BLFS) report on this Form 4?

BioLife Solutions reported an open-market sale of common stock by its Chief Technology Officer, Sean Werner. The filing shows a single transaction involving 111 shares of BioLife Solutions common stock, executed as a planned sale under a Rule 10b5-1(c) trading plan.

How many BioLife Solutions (BLFS) shares did the CTO sell and at what price?

The Chief Technology Officer sold 111 shares of BioLife Solutions common stock at a price of $20.74 per share. This transaction was recorded as a non-derivative open-market sale and is coded as a sale in open market or private transaction in the Form 4.

Why did the BioLife Solutions (BLFS) CTO sell shares according to the Form 4?

The filing explains that the sale was executed under a Rule 10b5-1(c) trading plan adopted by the reporting person. The stated purpose of this pre-arranged plan was to satisfy tax withholding obligations connected with the vesting of shares of restricted stock.

When was the Rule 10b5-1 trading plan for the BioLife Solutions (BLFS) CTO adopted?

The Form 4 notes that the Rule 10b5-1(c) trading plan used for this sale became effective on February 24, 2022. That plan governs the sale reported and was specifically adopted to handle tax withholding obligations arising from restricted stock vesting events.

How many BioLife Solutions (BLFS) shares does the CTO hold after this sale?

After the reported transaction, the Chief Technology Officer directly holds 49,932 shares of BioLife Solutions common stock. This post-transaction balance reflects ownership immediately following the sale of 111 shares disclosed in the Form 4 insider transaction report.